AI-generated analysis. Always verify with the original filing.
CRISPR Therapeutics AG announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting CASGEVY revenue of $54 million for Q4 2025 and $116 million for full year 2025, and a net loss of $130.6 million for Q4 2025. The company also provided business updates across its clinical pipeline including CASGEVY, in vivo liver editing programs, siRNA-based programs, and autoimmune/oncology programs.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On February 12, 2026, CRISPR Therapeutics AG announced its financial results for the quarter and year ended Decem
Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Relea
| Metric | Value | Basis |
|---|---|---|
| Revenue | $54.00 | |
| R&D Expenses | $83.50 | |
| G&A Expenses | $18.40 | |
| Collaboration Expense | $53.70 | |
| Net Loss | $130.60 |